A revolution in MS treatment

Advances in the past 20 years have improved prospects for many with MS

jamie lynn sigler

Actress Jamie Lynn Sigler recently revealed she’s been dealing with multiple sclerosis (MS) for 15 years, since she was 20 years old and starring in “The Sopranos.”

People across the country were wondering, ‘How did this successful and busy actress keep her MS diagnosis a secret from the press?’ Sigler said in interviews she was symptom-free for a long time, and now takes medication to keep her symptoms stable.

Continue reading

Multiple sclerosis: Unusual treatment holds new hope

Bolema twitter 3_full size

When I was diagnosed with multiple sclerosis (MS) in October 2000, I was only 26 years old. I had played football in college. I’d been active. I kept thinking, Now this. I was married but had no children at that point, and I wondered—with MS—what would my life have in store for me?

In a few years, the doctors I was seeing—even though they were neurologists—said they couldn’t do anymore for me than what they were already doing. One of the doctors put three medications in front of me and said, “This is what’s available for MS now. Choose one.” That’s how they approached the problem.

And that’s when I thought, I’m going to the University of Michigan.  Continue reading

New treatment for secondary progressive multiple sclerosis on horizon

U-M leads worldwide MS clinical trial

Multiple sclerosis (MS) is a major autoimmune disease that causes inflammation of the insulating
membranes (myelin) that surround the nerves within the central nervous system. MS onset is generally at the prime of life, between ages of 15 and 45. More than 500,000 people in the U.S. have MS, and there are 10,000 new cases every year. The University of Michigan Health System is actively involved in finding newer, better treatments for MS—and its related diseases.xray blog

As a physician and researcher in the area of multiple sclerosis (MS), I am often asked if there are new treatments and medications on the horizon. Thanks to years of research, the answer is yes, and I’m pleased to say that the University of Michigan is a major leader in some of the most important issues surrounding MS today. We’re trying to find the links between MS and other autoimmune diseases. We’re also conducting a new clinical trial and mechanistic study that may uncover a new treatment for secondary progressive MS. Approximately 85% of patients with newly diagnosed MS have relapsing-remitting MS . About 10-15 years after diagnosis, 50% of these patients will develop secondary-progressive MS , which is associated with significant disability. Finding a new treatment for this large group of people will make a significant impact on people’s lives. We’ve recently been given the tools to combat a disease that is a leading disabler of young adults.

Continue reading